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ScienceDirectThe maintenance of tissue homeostasis requires extracellular
matrix (ECM) remodeling. Immune cells actively participate in
regenerating damaged tissues contributing to ECM deposition
and shaping. Dysregulated ECM deposition characterizes
fibrotic diseases and cancer stromatogenesis, where a
chronic inflammatory state sustains the ECM increase. In
cancer, the ECM fosters several steps of tumor progression,
providing pro-survival and proliferative signals, promoting
tumor cell dissemination via collagen fibers or acting as a
barrier to impede drug diffusion. Interfering with processes
leading to chronic ECM deposition, as occurring in cancer,
might allow the simultaneous targeting of both primary tumors
and metastatic lesions. However, a note of caution comes
from data showing that defective ECM deposition is
associated with an exacerbated inflammatory and
autoimmune phenotype and to lymphomagenesis. Immune
cells display ITIM-inhibitory receptors recognizing collagens
as counter ligands, which negatively regulate the immune
response. This is in line with the idea that ECM components
can provide homeostatic signals to immune cells to regulate
and prevent unwanted activation, a concept particularly
relevant in cancer where these mechanisms could be in place
to keep infiltrating immune cells in a suppressive pro-tumoral
state. In this context, the pharmacological targeting of myeloid
cells, for which both direct and indirect roles in ECM
deposition have been shown, can be a relevant option to this
purpose.
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Tumor growth involves ECM deposition and remodeling.
This occurs through mechanisms that are common to
non-malignant processes of wound healing. The ECM
comprises different components including proteins,
glycoproteins, proteoglycans, structural proteins such as
collagens, laminin and tenascin, and matricellular pro-
teins (i.e. SPARC, osteopontin (OPN), thombospondins
[1–3]). Depending from tumor origin, differentiation and
grading, the amount of ECM deposition could vary.
Indeed, there are tumors characterized by a strong fibrotic
response with the formation of a dense and thick col-
lagenic capsule (e.g. follicular carcinomas of the thyroid),
by the formation of bundles around nests of packed tumor
cells (e.g. neuroendocrine malignant tumors), by intense
desmoplasia associated with dispersed tumor cell infiltra-
tion (e.g. some breast or gastric carcinoma histotypes), or
by evident stromal reaction with increased ECM confined
to the invasive edges (e.g. some colon adenocarcinomas).
The type and distribution of ECM stromal reaction to
malignant proliferation is related with the capability of
malignant clones to undergo epithelial-to-mesenchymal
transition, thought the mechanisms regulating the rela-
tionship between malignant clone differentiation, ECM
deposition and EMT have been poorly elucidated.
The relevance of the ECM for tumor progression has
been shown in pre-clinical mouse models and in human
specimens starting from breast cancer where large epide-
miological studies have shown that mammographic
density is an independent risk factor for breast cancer
development [4]. Mammographic density depends from
different factors including epithelial and stromal cells,
collagen and fat. All these elements are interconnected
and may affect each others increasing the risk for and the
progression of breast cancer [4]. More recently in high-
grade breast cancers a gene signature enriched in ECM
genes has been show to be capable of predicting response
to therapy and clinical outcome [5]. Similar ECM gene
clusters have been used to stratify colon cancer patients,
also correlating with histopathological parameters and
overall surgical staging [6]. ECM gene clusters have been
also described in ovarian cancer and in hematologic
tumors including diffuse large B cell lymphomas
(DLBCL) and non-Hodgkin lymphomas (reviewed in
Sangaletti et al. Cancer Immunology Immunotherapy
2017, [7]). Notably, it should be mentioned that some
genes are common among the different ECM clusters,Current Opinion in Pharmacology 2017, 35:75–82
76 Cancersuch as COL1A1, LOX, SPARC and TIMP3 or belong
to the same gene family (i.e. MMPs, Collagen, FN or
tissue inhibitors of metalloproteinases) suggesting that
common ‘wound healing’ mechanisms may be activated
by tumors of different tissue origin to progress. Further-
more this means that common targets could be potentially
identified within ECM molecules that could be used to
implement current therapies, irrespective from tumor
histotype.
Mouse and human data suggest the importance of colla-
gen deposition and cross-linking for tumor development.
For example the presence of fibrotic foci has been asso-
ciated with a higher relapse rate and a worse overall
survival in breast cancer [8,9]. Using the 4T1 triple
negative breast cancer model, Cox and coll. showed that
metastasis formation occurs at the site of hypoxia-driven
fibrotic response and that abrogation of lysyl oxidase
(LOX)-mediated collagen cross-linking prevent lung
metastases [10]. The same authors profiled a cohort of
344 lymph node — negative primary breast cancer
patients identifying that an hypoxic signature, originally
described by Chi et al. [11], was closely associated with
poor survival and metastasis in estrogen receptor negative
(ER) breast cancer patients [12]. Indeed, the hypoxic
secretome from bone-tropic and parental ER human
breast cancer cells identified the ECM modifying LOX
as the protein more significantly associated with bone
metastases in ER patients, but not in ER+ patients [12].
Further relevance of ECM and ECM-related cluster
(including SPARC, COL1A1, COL3A1) variation has
been shown to occur during tumor progression including
their down-modulation in certain hemathologic malig-
nancies, like CD5+ DLBCL and B-CLL, characterized
by abnormal expansion of CD5+ B cells [13]. Accordingly,
we have recently shown that the lack of SPARC in
secondary lymphoid organ (SLO) microenvironment of
autoimmunity-prone mice favors the development of a B-
CLL like disease [14]. On the contrary, crossing lym-
phoma-prone Trp53-deficient with Sparc-deficient mice,
protects them from the development of DLBCL and
follicular lymphomas [15]. These studies suggest that
either the increase or the decrease of the ECM can impact
on tumor progression.
Myeloid cells and ECM remodeling
Myeloid cells participate in ECM organization at differ-
ent levels, being able of producing enzymes/mediators
capable of ECM remodeling or of producing directly
ECM molecules.
Within the tumor microenvironment myeloid cells that
are skewed towards a pro-tumoral phenotype (being
MDSCs, M2 macrophages or N2 neutrophils) are the
main source of matrix metalloproteinases (MMPs),
enzymes involved in collagen remodeling [16]. In thisCurrent Opinion in Pharmacology 2017, 35:75–82 context, zoledronic acid (ZA)-treatment of transgenic
mice carrying the mutated HER-2 protein and develop-
ing mammary tumors, reduces local MMP-9 production
and results in impaired expansion of myeloid cell com-
partment, enrichment and differentiation to tumor-
associated macrophages (TAMs) at the tumor site. These
events also impair tumor stroma formation and collagen
deposition [17]. In line, the growth of mammary tumors in
MMP-9-deficient mice is associated to defective collagen
fibers formation and reduced tumor growth (Sangaletti,
unpublished).
The matricellular protein SPARC is a collagen chaperone
and a master stromal regulator [18]. Studies in Drosophila
and mouse have shown that SPARC is required for collagen
type IV fibers production and assembly into basal mem-
branes [19,20], as well as for fibronectin-induced integrin-
linked kinase activation and collagen deposition in fibrotic
condition [21,22]. Genetic deletion of Sparc affects tissue
remodeling and tumor-stroma deposition with conse-
quence on primary tumor growth and/or metastasis, which
can vary depending on the tumor histotype [23]. In a model
of breast cancer, we have demonstrated that the absence of
SPARC reduces primary tumor growth and lung metasta-
ses, an effect due to the incapacity of Sparc-deficient
macrophages to sustain collagen deposition and stroma
formation [20], as well as tumor cell migration on fibronec-
tin and collagen fibers [24]. These data suggest that macro-
phages can be a relevant source of ECM proteins during the
critical process of tumor growth. A formal demonstration
that TAMs can produce ECM molecules has been obtained
from integrating transcriptomic and proteomic analysis on
these cells [25]. Combining these two approaches, Afik
and coll. have shown that TAMs are thesource of molecules
associated with collagen synthesis, stability, assembly, and
cross-linking. Among them the a1 chains of collagen I and
collagen XIV, the three a chains of collagen VI, the glyco-
protein PCOLCE, the enzyme P4HA1, collagen cross-
linkers PLOD1 and 3, the glycoprotein SPARC, and the
proteoglycan biglycan. Their integrative analysis also
highlighted the TAMs produce the ECM covalent cross-
linker enzymes TGM2 and F13A1, the complement C1q
complex, and THBS1. Overall these data showed that
TAMs directly contribute in building specific types of
collagenous ECM. Supporting this finding the same
authors showed that colorectal cancer grown in TAM-
deficientCcr2/ mice hadaberrantdepositionofcollagen
fibers. Furthermore, TAMs can regulate collagen produc-
tion by cancer-associated fibroblasts (CAFs), whose num-
beroutcompeted that of macrophages in the analyzed colon
cancer model [25]. The mechanisms for such a cross-talk
was not described. It can be speculated that IL-4 and IL-13,
produced by TAMs, mediate such interaction, similarly to
what has been described in a model of skin repair [26].
In such skin injury model the authors demonstrated that
IL-4/IL-13 signaling through the cognate IL-4Rawww.sciencedirect.com
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the architecture of collagen fibrils and the biochemistry of
collagen cross-linking, which in the wounded skin is
operated by fibroblasts [26]. The authors identified
Relm-a as the mediator that, released by IL-4/IL-13-
stimulated macrophages, promotes the production of
collagen cross linker LH2 in fibroblasts.
Overall these data suggest that targeting myeloid cells/
macrophages within the tumor microenvironment could
be a strategy to interfere with the excessive collagen
deposition that often characterizes the tumor
microenvironment.
The bi-directional cross-talk between ECM
and myeloid cells
Other than participating in ECM organization, ECM mole-
cules are endowed of regulatory capacity over myeloid cell
functions. ECM bioactive fragments, generated by MMPs
digestion of collagens and laminins (also termed matricryp-
tins or matrikines [27,28]) can be chemotactic for myeloid
cells, suggesting that in the tumor microenvironment an
altered ECM deposition associated with the production of
MMPs can generate a condition promoting tumor infiltra-
tion by myeloid cells. Interestingly other than releasing
chemotactic fragments, collagen can contribute to myeloid
cell recruitment at the tumor site by regulating other
pathways including the CXCR4-COX-2 axis. In this con-
text we have recently shown that increased collagen depo-
sition and SPARC expression in breast tumors, activate
COX-2 that in turn promotes a CXCR4-mediated recruit-
ment of MDSCs at the tumor site [29]. Myeloid cells are
not the only cell type that can be affected by collagen fibers;
T lymphocytes and macrophages also use collagen fibers to
migrate into inflamed tissues [30,31]. Considering the
mechanism used by myeloid cells and T lymphocytes to
migrate through the ECM, Wolf and coll. have shown that
migration of T cells and other leukocytes within 3D colla-
gen matrices occurs through an amoeboid process impli-
cating the crawling along collagen fibrils (contact guidance)
[32] and not involving proteases. This process can involves
integrin receptors; indeed it has been shown that the
crawling of effector T cells on ECM in inflamed tissues
requires avb1 and avb3 activation [33].
The current idea is that immune cells can use different
mechanismsto migrate across or through the ECM depend-
ing from the composition and organization of the ECM
itself.
Other than regulating leukocyte migration, recent evi-
dence indicates that the ECM can generate signals within
immune cells capable of interfering with their state of
activation.
Immune inhibitory receptors are a class of ITIM-bearing
receptors whose engagement inhibits cellular activationwww.sciencedirect.com [34]. Among ITIM-bearing receptors, LAIR-1 is of spe-
cial interest for those studying the immune implication of
ECM [35]. Indeed LAIR-1 binds to and is inhibited by
collagens, corroborating the hypothesis of a bi-directional
regulation between ECM molecules and immune cells
[36]. LAIR-1 is expressed by the majority of hematopoi-
etic cells, although its expression varies according to the
state of differentiation and activation of the different
immune cells. It is expressed by myeloblasts and pro-
myelocites, but not by bone marrow or circulating neu-
trophils in which its re-expression occurs upon activation
(inflammatory cytokines, LPS, PMA, [37]). In activated
neutrophils LAIR-1 engagement by collagens has been
shown to inhibit neutrophil extracellular trap (NET)
extrusion, upon IFNg + C5a stimulation [14]. Consider-
ing that abnormal neutrophil activation and death through
NETosis is a relevant step in autoimmunity, it could be
suggested that blocking ECM-mediated neutrophil inhi-
bition could promote an autoimmune reaction. On this
line, we demonstrated that the absence of the matricel-
lular protein SPARC, in Fas-deficient mice, was associ-
ated to an altered SLO collagen remodeling leading to an
unwanted neutrophil activation and NETosis, exacer-
bated autoimmunity and lymphomagenesis. The last
was linked to NET stimulation of abnormal and clonal
proliferation of CD5+ B cells towards a B-CLL like
disease [14]. Notably, among human lymphomas, B-
CLL is characterized by a reduced ECM deposition as
compared to follicular, mantle cell and diffuse large B-cell
lymphomas, all showing higher deposition of collagen
matrix [14]. A similar contribution of NETs in malignant
progression has been shown in solid tumors, as exempli-
fied by breast cancer cell stimulation of neutrophil
NETosis and subsequent NET support of metastasis
formation [38]. Accordingly, NETs stimulate the inva-
sion and migration of breast cancer cells in vitro. Inhibit-
ing NET formation or digesting the NET DNA thread
using deoxyribonuclease I (DNase I) blocks the meta-
static process. These mechanisms have been shown in the
murine model of triple negative breast cancer, 4T1.
Interestingly, this model is widely used to study MDSC
function and expansion [39], suggesting the possibility
that MDSCs and NET-prone neutrophils could co-exist
or, alternatively, that NETs could be extruded by
MDSCs. In another breast cancer tumor model
(SN25ASP, [29]), we found that splenic MDSCs isolated
from tumor-bearing mice and seeded onto poly-D-lysine
coated glasses become able of extruding NETs if treated
with the canonical PMA stimulus (Sangaletti, Unpub-
lished). Melero and coll. have recently shown that IL-8
attracts both monocytic (M-MDSCs) and granulocytic (G-
MDSCs) human MDSCs that, respectively, suppress the
proliferation of autologous T cells or extrude NETs
under IL-8 stimulation [40]. These findings are appar-
ently contradictory with the common interpretation of
NET induction associated to autoimmune [41] or infec-
tion conditions, whereas in case of MDSCs they shouldCurrent Opinion in Pharmacology 2017, 35:75–82
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ing explanation could come from considering NET extru-
sion as an ancestral prerogative of myeloid cells,
conserved along differentiation. Indeed NETs are
extruded also by immature myeloid cells (Sangaletti,
unpublished observation) and are stimulated by specific
cytokines that could be present in both suppressive and
activated immune microenvironment (i.e. TNF and
IFNg), consistently with their dual role. Considering the
relevance of LAIR-1 in inhibiting NETosis, we evaluated
the expression of LAIR-1 in the two subset of MDSCs
infiltrating mousemammary tumors andfoundthat LAIR-1
is expressed in both subsets of MDSCs, although at differ-
ent level, suggesting that in the tumor microenvironment
G-MDSCs and M-MDSCs could be differently regulated
by ECM collagens. For example we can hypothesize that
collagens, as LAIR-1 ligands, in the tumor microenviron-
ment can participate in keeping M-MDSCs with a sup-
pressive phenotype or in limiting NET extrusion.
Neutrophils are not the only immune cell subset expres-
sing LAIR-1 in the tumor microenvironment. T lympho-
cytes, according to their state of activation, can express
LAIR-1 at different levels. In such a context it has been
shown that naive CD4+ and CD8+ T cells, as well as CD8
+ effector T cells, express higher levels of LAIR-1 than
memory T cells [42]. In vitro T cell stimulation decreases
LAIR-1 expression, a finding that needs to be confirmed
in vivo. Furthermore, crosslinking of LAIR-1 on primary
T cells results in an inhibition of T cell function [42].
These pieces of evidence suggest that microenviron-
ments differently enriched in collagens can be detrimen-
tal for local T cell activation but also for antigen presen-
tation, being LAIR-1 also expressed by professional
antigen presenting cells. In such a context, it has been
shown that LAIR-1 can limit DC differentiation and
activation, although through the binding of C1q and
not collagens [43]. It could be argued that local interfer-
ence with ECM remodeling can putatively ameliorate
antigen-mediated immune responses. More difficult is
the prediction of whether this approach could be benefi-
cial in case of tumors infiltrated by myeloid cells, since, on
one hand, M-MDSCs could be reverted from their sup-
pressive function, whereas on the other, G-MDSCs, could
be excessively stimulated to undergo NETosis and there-
fore contribute to metastases (Figure 1).
On the basis of these considerations it could be argued
that, as occurring for immune check-point inhibitor-based
therapy, the use of collagen-interfering strategies should
be considered only after a precise assessment of the
composition of the tumor immune infiltrate.
Strategies to target ECM deposition in the
tumor microenvironment
Both direct and indirect strategies to target ECM deposi-
tion can be envisaged. The first approach can includeCurrent Opinion in Pharmacology 2017, 35:75–82 molecules able to interfere directly with ECM deposition
or remodeling, that is, anti-fibrotic agents, whereas the
second strategy aims at targeting the ECM indirectly by
affecting the function or the recruitment of myeloid cells.
TGF-b is certainly a relevant possible target to affect ECM
deposition in cancer. Indeed it has been directly involved in
collagen matrix deposition by activated fibroblasts or in
EMT induction. Moreover TGF-b act as an immune
regulator decreasing tumor immune surveillance [44].
Results obtained in vitro or in mouse models with TGF-b
inhibitors showed that these compounds poorly affected
tumor cells while exerted their anti-tumoral activity
mainly on stromal and immune cells in the tumor micro-
environment This suggests that these compounds could
be more effectively used in combination with che-
motherapies. For example, this approach could be
relevant in setting in which fibrosis precedes tumor
development, such as in breast cancer. However, treat-
ments affecting TGF-b signaling should take into con-
sideration the dual role of TGF-b in cancer progression,
especially for nascent tumors. Indeed, different mouse
models have shown that genetic deletion or down-regu-
lation of TGF-b signaling worsened the tumor pheno-
type. This effect is due to the fact that TGF-b suppresses
tumor initiation and early development through inhibi-
tion of cell cycle progression, induction of apoptosis, and
suppression of growth factor, cytokine and chemokine
expression. The goal of TGF-b inhibition-based thera-
pies is now to abolish the tumor-promoting effect of
TGF-b, while maintaining its tumor suppressive
properties.
IL-13 is the most extensively studied Th2 cytokine in the
context of idiopathic pulmonary fibrosis (IPF). Indeed, in
a mouse experimental model of pulmonary fibrosis IL-13
targeting therapies successfully attenuated the fibrotic
phenotype [45] and anti-IL13 antibodies have been used
in clinical trial for IPF treatment [46]. Within the tumor
microenvironment, this cytokine, together with IL-4,
promotes the development of TAMs and their production
and cross-linking of ECM molecules suggesting that
IL-13-directed therapies can be a possible approach to
target the ECM-rich tumor microenvironment [25].
LOX is another potential target within the ECM. Indeed
the relevance of LOX activity on metastases has sug-
gested that his targeting could be particularly relevant in
case of metastatic disease [12]. However, small LOX
inhibitors are currently not yet available, because of
the lack of a complete crystal structure that excludes it
from classical structure-driven fragment-based drug
development and screening approaches.
A possible strategy to indirectly target the ECM deposi-
tion in cancer is to use bisphosphonates [47]. These drugswww.sciencedirect.com
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Figure 1
Effect of ECM targeting on immune cell functions in the tumor microenvironment. Within the tumor microenvironment macrophages and
fibroblasts (CAF) contribute to ECM deposition. ECM components can recruit MDSCs and regulate their immunosuppressive functions [29].
The collagen receptor LAIR-1 transduces negative signals to granulocytes/G-MDSCs that no longer undergo NETosis, which has been described
to promote metastases [38,40]. The lack/reduction of ECM signals can switch MDSCs towards a less suppressive phenotype. We can
hypothesize that ECM targeting can hamper local tumor-associated immunosuppression unleashing DCs from negative signals favoring
migration to lymph node and antigen presentation activity [43]. In addition the reduction of ECM signals can redirect macrophages and myeloid
cells from pro-tumoral to anti-tumoral activity. Nevertheless ECM degradation or reduction can foster NET formation by G-MDSC and in turn
promote metastases.
www.sciencedirect.com Current Opinion in Pharmacology 2017, 35:75–82
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the loss of bone mass in osteoporosis. Our group has
shown in different studies performed in breast cancer
models, that zoledronic-acid (ZA), the most active and
clinically approved third-generation amino-bisphospho-
nate, can affect tumor growth and metastasis through its
ability to interfere with myeloid cell expansion and
suppressive function [29]. Inhibiting MDSCs with ZA,
we were able of reverting EMT and halting metastasis in
high-grade, SPARC-expressing mammary tumors [29].
Other groups have shown that ZA can affect myeloid cell
differentiation. In mesothelioma ZA leads to reduced
macrophage infiltration and impairs their polarization
towards an M2 phenotype, a phenotype that, however,
was associated with an increased number of immature
myeloid cells, which, as suggested by the authors, could
on the other hand diminish the effects of ZA on survival
[48]. Very recently it has been shown that ZA adminis-
tration modifies the BM stem cell niche inducing tran-
sient changes in the number of hematopoietic stem cells,
myeloid-biased and lymphoid-biased progenitor cells.
The same authors showed that BM cells from mice
treated with a single, clinically relevant, dose of ZA
inhibited mammary tumor outgrowth in vivo, when co-
injected with tumor cells [49]. Overall these studies
suggested that ZA can affect myeloid cell recruitment,
expansion and pro-tumor phenotype. Our observation in
BALB-NeuT mice treated with ZA or in SPARC-expres-
sing high-grade mammary tumors indicated that ZA
treatment also affects collagen deposition within the
tumor microenvironment, as ZA-treated tumors displayed
reduced collagen deposition ([17] and Sangaletti et al.
unpublished). Interestingly, Cox et al. showed that ZA
completely blocked the formation of focal premetastatic
osteolytic lesions and almost completely eliminated the
tumor burden in metastatic models of breast cancer
through the targeting of the downstream activities of
LOX, namely, the de novo generation of functionally
active osteoclasts [12]. Different studies have suggested
the relevance to use bisphosphonate as anticancer agents
in breast cancer also in early breast cancer [50]. Overall
clinical trials with bisphosphonates as adjuvant therapy
for breast cancer showed contrasting results [51], suggest-
ing that a selective rather than a broad administration of
this drug could be the best approach. Indeed, the efficacy
of ZA administration can be potentially dependent from
different factors, including hormone status, p53 muta-
tional status or tumor grade. Indeed, tumor cells bearing
mutant p53 have enhanced mevalonate pathway activity
and may be particularly sensitive to inhibition [52] and
our recent studies showed that high-grade breast cancers
with a specific ECM signature could benefit from ZA
treatment [29].
Finally, considering that tumor-associated fibroblasts are
key regulators of ECM deposition and tumor growth,
vaccine specifically targeting fibroblast activation proteinCurrent Opinion in Pharmacology 2017, 35:75–82 (FAP), which is specifically overexpressed by fibroblasts
in the tumor stroma, can be a possible strategy to halt
tumor growth [53]. Indeed there are preclinical data,
obtained with mouse models, showing that FAP-vacci-
nated mice had markedly decreased collagen type I
expression and increased uptake of chemotherapeutic
drugs [54].
Concluding remarks
Growing body of evidence suggests that targeting the
ECM is feasible and that this new approach could
improve the efficacy of anti-cancer therapies. However
a note of caution stems from the less appreciated immu-
noregulatory role of ECM proteins. Therefore ECM
targeting might, on one hand, limit tumor-associated
immune-suppression unleashing immune cells from
inhibitory signals and, on the other, exacerbate immune
cells activation towards autoimmune-like responses.
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